Tirzepatide and Erectile Dysfunction: What Weight Loss and the Early Data Show

Tirzepatide and erectile dysfunction (ED) have been studied together only in observational research and one small pilot study, and so far those studies point toward fewer new ED diagnoses and better erection scores rather than more. In a 2025 cohort study of men with type 2 diabetes, tirzepatide was associated with a 30% to 45% lower risk of a new ED diagnosis or PDE5 inhibitor prescription than three other diabetes medicines. No randomized trial has tested tirzepatide for sexual function, however, and tirzepatide is not approved to treat erectile dysfunction. Obesity, insulin resistance and low testosterone all make erectile problems more likely, and tirzepatide changes all three, while a separate database study raised a concern about semaglutide and ED in younger men. This guide covers what each study measured and why weight loss itself matters.

Does tirzepatide cause erectile dysfunction?

Current evidence does not show that tirzepatide causes erectile dysfunction, and the largest study that looked at tirzepatide specifically found the opposite association. That study, published by Cowart and colleagues in the Journal of Diabetes and its Complications in 2025, used the TriNetX health records network to follow men aged 18 to 70 with type 2 diabetes and no prior ED between May 13, 2022 and May 17, 2025. The researchers built three 1:1 propensity matched comparisons and counted either a new ED diagnosis or a new prescription for a PDE5 inhibitor such as sildenafil.

Across every comparison, men on tirzepatide had fewer of those events, with risk ratios of 0.70 against sitagliptin, 0.67 against injectable semaglutide and 0.55 against dulaglutide. The authors wrote that "randomized trials are needed to confirm these findings," because men who receive one drug instead of another may differ in ways matching cannot fully remove.

A 2025 analysis by Pourabhari Langroudi and colleagues in the International Journal of Impotence Research, drawing on the FDA Adverse Event Reporting System, covering reports from 2003 to 2024, found 182 cases of male sexual dysfunction linked to GLP-1 medicines including tirzepatide. The reporting odds ratio of 0.41 suggested a weak association, and the authors judged overall patient risk to be low.

Can tirzepatide improve erectile function?

Whether tirzepatide improves erectile function is not established; the direct evidence comes from one short pilot study in men with obesity. La Vignera and colleagues published that study in Reproductive Biology and Endocrinology in 2025. It enrolled 83 men with obesity and metabolic hypogonadism, which is low testosterone driven by excess weight and insulin resistance, with a mean age of 55.3.

Every man followed a reduced calorie diet and walked briskly for 20 minutes a day. Twenty eight men also received tirzepatide, starting at 2.5 mg weekly for a month and then 5 mg; 30 men had no medicine; and 25 men used transdermal testosterone. After 2 months, the tirzepatide group had larger drops in weight, waist size and fat mass and a notable increase in IIEF-5 score, the standard five question erection questionnaire, compared with both other groups. Total, free and bioavailable testosterone rose more in the tirzepatide group as well, while estradiol fell.

Several limits matter here. The study was not randomized, the groups differed at the start in waist size, lean mass and hormone levels, and two months is a short window. A 2026 meta-analysis in the World Journal of Methodology pooled 7 studies with 237 men on GLP-1 class medicines and found an average improvement in ED scores of 2.73 points, along with higher total testosterone, but the authors again called for larger randomized trials.

Why would weight loss affect erections?

Weight loss can affect erections because erectile function depends on healthy blood vessels, and excess weight harms the vessel lining, raises inflammation and lowers testosterone. A review in Biomolecules describes ED as a common microvascular complication of diabetes, affecting up to three out of four people with the condition, with insulin resistance and androgen deficiency among the main contributors.

The strongest evidence that losing weight helps comes from a trial that used no medicine at all. Esposito and colleagues randomized 110 men with obesity and ED, defined as an International Index of Erectile Function (IIEF) score of 21 or less, in a JAMA trial published in 2004. The 55 men in the intervention group received detailed coaching to lose 10% or more of their body weight through eating less and moving more, while the 55 controls received general healthy living advice.

After 2 years, the intervention group's average IIEF score rose from 13.9 to 17, while the control group moved from 13.5 to 13.6. Seventeen men in the intervention group reached a score of 22 or higher, the range usually read as no ED, compared with 3 men in the control group. Changes in body mass index, physical activity and C reactive protein each tracked independently with the improvement, and the authors summarized the benefit as reaching about one third of the men.

That trial suggests why a medicine producing large weight loss could plausibly help erections, and also that the benefit is partial, since most men in the intervention group did not reach normal scores.

What about the semaglutide ED study?

A 2024 database study raised the possibility that semaglutide is linked to more ED in younger men without diabetes, and that study is the main reason the question circulates online. Able and colleagues, writing in the International Journal of Impotence Research, used TriNetX records for men aged 18 to 50 with a BMI over 30 and no diabetes. After matching, the average man was 37.8 years old with a BMI of 38.6.

Men prescribed semaglutide had more new ED diagnoses or PDE5 inhibitor prescriptions than matched men who never received it, at 1.47% versus 0.32%, and more testosterone deficiency diagnoses, at 1.53% versus 0.80%. The absolute numbers are small, and men starting a prescription weight loss medicine see a clinician more often, which creates more chances for ED to be diagnosed. The study did not include tirzepatide, and unlike the Cowart study it compared treated men with untreated men, so the two answer different questions and neither proves cause and effect.

Does tirzepatide affect testosterone?

Tirzepatide appears to raise testosterone in men whose low levels are tied to obesity, based on the La Vignera pilot study, although larger trials have not confirmed this. Higher LH and FSH in that study suggest the body's own hormone signaling recovered, while the 2026 meta-analysis found higher total testosterone but no significant change in free testosterone or LH. For a broader look at how GLP-1 therapy and male hormones interact, see the Aurelius guide to GLP-1 therapy and testosterone in men.

What else can change sexual function during treatment?

Eating much less than usual, nausea or fatigue during a dose increase, and dehydration can all lower energy and interest in sex during tirzepatide treatment. Blood pressure often falls with weight loss, and PDE5 inhibitors lower it too, so a review of tirzepatide and other medications is useful early on.

When should a man talk to a clinician about ED?

A man should talk to a clinician whenever ED is new, persistent or bothersome, because erectile problems can be an early sign of cardiovascular disease or diabetes and can also reflect low testosterone, medicines or mood. PDE5 inhibitors must not be combined with nitrates, so they should be prescribed only after a review of the full medication list.

Frequently asked questions